Evidence map›Paper›PMID 38815957›Full record

ArticleCanadian journal of ophthalmology. Journal canadien d'ophtalmologie2025

Posterior capsular opacification and YAG laser capsulotomy in uveitis patients following cataract surgery.

Grace A Levy-Clarke, Craig W Newcomb, Gui-Shuang Ying, Sylvia L Groth, Srishti Kothari, Abhishek Payal, Hosne Begum, Teresa L Liesegang, C Stephen Foster, Douglas A Jabs and 11 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Grace A Levy-ClarkeDepartment of Ophthalmology, West Virginia University Eye Institute, Morgantown, WV; Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD.
Craig W NewcombCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Gui-Shuang YingDepartment of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Sylvia L GrothVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN.
Srishti KothariDivision of Child Care Services, New York State Office of Children and Family Services, Westchester Regional Office, Valhalla, NY.
Abhishek PayalDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
Hosne BegumDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
Teresa L LiesegangDepartment of Ophthalmology, Oregon Health and Science University, Portland, OR.
C Stephen FosterDepartment of Ophthalmology, Harvard Medical School, Boston, MA; Massachusetts Eye Research and Surgery Institution, Waltham, MA.
Douglas A JabsDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Robert NussenblattLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD.
James T RosenbaumDepartment of Ophthalmology, Oregon Health and Science University, Portland, OR; Department of Public Health and Preventive Medicine, Oregon Heath and Science University, Portland, OR; Legacy Devers Eye Institute, Portland, OR.
H Nida SenLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD.
Eric B SuhlerDepartment of Ophthalmology, Oregon Health and Science University, Portland, OR; Portland Veteran's Affairs Medical Center, Portland, OR.
Jennifer E ThorneDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Nirali P BhattDepartment of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Kurt A DregerDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Population, Family, and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Jeanine M BuchanichCenter for Occupational Biostatistics and Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA.
John H KempenDepartment of Ophthalmology, Harvard Medical School, Boston, MA; Sight for Souls, Fort Myers, FL; Departments of Global Health and Social Medicine, Harvard Medical School, Boston, MA; MCM Eye Unit, MyungSung Christian Medical Center (MCM) General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia; Department of Ophthalmology, Addis Ababa University School of Medicine, Addis Ababa, Ethiopia.
Sapna GangaputraVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN. Electronic address: sapna.gangaputra@vumc.org.
Systemic Immunosuppressive Therapy for Eye Diseases Research Group

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Outcomes of uveitic cataract and uveitic glaucoma surgeryR21EY032592 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GANGAPUTRA, SAPNA S · 2021 to 2022
$488k
NEI NIH HHS R01 EY014943NEI NIH HHS R21 EY032592
6 · The paper itself

Abstract

objectiveTo evaluate the incidence of visually significant posterior capsule opacification (PCO with visual acuity ≤20/50) and the incidence of Nd:YAG laser capsulotomy in the year following cataract surgery for uveitic eyes.

methodPatients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study using a standardized chart review process.

resultsAmong 1,855 uveitic eyes of 1,370 patients who had undergone cataract surgery, visually significant PCO occurred in 297 eyes (16%), and YAG laser capsulotomy was done in 407 eyes (22%) within the first year following surgery. Higher odds of developing 20/50 visual acuity attributed to PCO were noted in children and young adults compared with adults older than 65 years of age (overall p = 0.03). Poorer preoperative visual acuity (overall p = 0.0069) and postoperative inflammation (odds ratio [OR] = 1.83; 95% CI, 1.37-2.45; p < 0.0001) were associated with PCO incidence. In multivariable analysis, risk factors for YAG laser capsulotomy were younger age groups compared with those older than 65 years of age at the time of surgery (adjusted OR [aOR] = 1.90-2.24; 95% CI, 1.90-2.24; overall p = 0.0007), female sex (aOR = 1.37; 95% CI, 1.03-1.82; p = 0.03), postoperative active inflammation (aOR = 165; 95% CI, 1.27-2.16; overall p < 0.0001), extracapsular cataract extraction compared with phacoemulsification (aOR = 1.70; 95% CI, 1.17-2.47; overall p < 0.0001), and insertion of an intraocular lens (aOR = 4.60; 95% CI, -2.29-9.25; p < 0.0001). Black race was associated with lower YAG laser capsulotomy incidence than Whites (aOR = 0.36; 95% CI, 0.24-0.52; overall p < 0.0001).

conclusionsVision-reducing (≤20/50) PCO is common, occurring in about one sixth of uveitic eyes within 1 year of cataract surgery; a higher number (22%) of eyes underwent YAG laser capsulotomy within the first year. Age and postoperative inflammation following cataract surgery are the variables most associated with the incidence of visually significant PCO and YAG laser capsulotomy.

Indexed as

Capsule OpacificationCataract ExtractionLasers, Solid-StateLaser TherapyPosterior Capsule of the LensPosterior CapsulotomyPostoperative ComplicationsUveitisAdolescentAdultAgedAged, 80 and overChildFemaleFollow-Up StudiesHumans

Identifiers

PMID38815957
PMCPMC11599466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.